ElaineWalshMDMB BCh PhD

Oncology • Washington, DC

Breast Cancer

Medical Oncologist, MedStar Georgetown University Hospital

Join to view full profile

Dr. Walsh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walsh's full profile

Already have an account?

Office
3800 Reservoir Rd NW
Washington, DC 20007
Phone+1 202-444-2223

Fax+1 866-871-7844

Education & Training

Royal College of Physicians of IrelandCertificate of Satisfactory Completion of Specialist Training, Medical Oncology, 2015
Royal College of Physicians of IrelandMember RCPI, 2009
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2017 - 2020
National University of Ireland, GalwayPhD, 2015 - 2019
National University of Ireland, GalwayClass of 2006

Certifications & Licensure

MD State Medical License 2023 - 2025
NY State Medical License 2020 - 2025
DC State Medical License 2022 - 2024
NJ State Medical License 2021 - 2023

Clinical Trials

STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Recruiting
Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

1 citations
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma
EMBO Molecular Medicine. 2024-08-01
7 citations
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Elaine M Walsh, Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S Ross
Breast Cancer Research and Treatment. 2022-10-01
29 citations
Accelerating drug development in breast cancer: New frontiers for ER inhibition.
Emanuela Ferraro, Elaine M Walsh, Jacqueline J Tao, Sarat Chandarlapaty, Komal Jhaveri
Cancer Treatment Reviews. 2022-09-01

Lectures

The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast ca...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

Gathering Together to Tackle CancerNovember 25th, 2020